> 回列表
UBIP Emerging Stock Board Pre-Listing Presentation is Held Today
2016/1/21
 

United Biomedical Inc., Pharma (UBIP, code 6562) held a company presentation today prior to its January 22 listing on Taiwan Emerging Stock Board. UBIP was established on July 31, 2014 as a spin-off company from United Biomedical Inc., Asia, its three main businesses are biosimilars/biobetters, specialty injectables and contract research/manufacturing.  Formosa Biomedical Technology Corp., the second largest shareholder, is UBIP’s strategic partner.

The biosimilar/biobetter business focuses on developing difficult-to-express and long-acting protein drugs, e.g. erythropoietin (EPO), Interferon (IFN)-a, IFN-b, and granulocyte colony stimulating factor (GCSF). EPO biosimilar UB-851 is approved for phase III clinical trial, targeting to bring the first biosimilar developed in Taiwan to commercialization. Long-acting protein drugs designed on an exclusively owned sFc fusion protein platform have shown 4-10 times longer in vivo half-life in animal studies. This technology could significantly lower the drug administration frequency, making our products more user-friendly.

UBIP’s GMP facilities are certified by the regulatory authorities in the US, Japan, Australia, and Columbia, providing manufacturing services to large pharmas, such as GSK, Pfizer, J&J, and Adimmune Corporation. UBIP’s US-oriented sterile specialty injectable manufacturing lines are also US FDA certified and can generate considerable revenue.

UBIP’s growth plans make UBIP a unique company in Taiwan’s biotechnology  industry. UBIP had positive net income in the two years after establishment and its net income is expected to grow sharply after biobetter products are launched. UBIP’s ultimate goal is to become the global leader of protein drugs and specialty injectables.

For more information, please visit http://unitedbiomedical.org/?p=15406


About United Biomedical, Inc., Pharma (6562)
UBIP was established in August 2014 as a spin-off company from UBIA, specializing in the development, manufacturing, and marketing of innovative fusion protein drugs and specialty injectables. In addition, UBIP has the only US FDA certified sterile injectable filling line in Asia outside of Japan. UBIP also provides contract development and manufacturing services. For more information, please visit: http://www.ubi-pharma.com

Contact:
Ying-Yun Vivien Fan
Director of Public Relations and Spokesperson
Telephone: 886-3-597-7676 ext. 2113

PR@unitedbiopharma.com
E-mail:vivien.fan@ubi-pharma.com